We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Radient Pharmaceuticals Announces Preliminary Results from its Onko-Sure® Clinical Study
Product News

Radient Pharmaceuticals Announces Preliminary Results from its Onko-Sure® Clinical Study

Radient Pharmaceuticals Announces Preliminary Results from its Onko-Sure® Clinical Study
Product News

Radient Pharmaceuticals Announces Preliminary Results from its Onko-Sure® Clinical Study


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Radient Pharmaceuticals Announces Preliminary Results from its Onko-Sure® Clinical Study"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Radient Pharmaceuticals Corporation has announced that preliminary results from its clinical study conducted in collaboration with a well-recognized, large third-party not-for-profit group practice and its affiliates for the validation of RPC's US FDA-cleared Onko-Sure® in vitro diagnostic (IVD) cancer test.

The purpose of the study was to determine the effectiveness of Onko-Sure® (DR-70) as a useful tool in the detection of colorectal cancer in all stages of colorectal cancer (CRC), especially early stages where effective diagnosis leads to better patient prognosis. In addition, this study focused on the effectiveness of Onko-Sure®, Carcinoembryonic Antigen (CEA) and the combination of these two tumor markers for additional clinical value.

Based on preliminary results, RPC's Onko-Sure® IVD cancer test shows a statistical advantage over CEA in detecting CRC in the early stages of colorectal cancer. Furthermore, when Onko-Sure® was combined with CEA, the sensitivity of the combined test was substantially improved as opposed to using CEA alone.

RPC plans to disseminate these results in a peer-reviewed journal, either independently or with other third party healthcare organizations. Additionally, RPC plans to present these results to physicians at international oncology conferences and scientific meetings.

RPC's Executive Chairman and CEO Douglas MacLellan commented, "We are pleased by the preliminary findings of the study and anxiously await the final data set analysis. We acknowledge the diligence and hard work that supporting teams have put into the study. Furthermore, we sincerely appreciate the loyalty of our committed staff and shareholders."

The Company also filed an extension today with the SEC to file its annual report on Form 10-K for the year ending December 31, 2010 on or before April 15, 2011, which is the permissible extension date.

Advertisement